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INTRODUCTION
Testosterone use in the USA has risen steeply with a nearly 10-fold increase since 2000 [1 && ]. This increase occurred in the context of large increases in direct advertising to consumers for treatment of 'low T' with nearly $3.5 billion spent in 2012 [2, 3] . The availability of T-gel formulations and the hope that testosterone may maintain youthfulness may have also helped to fuel the increase in testosterone use. However, testosterone treatment is only approved for men with symptoms of androgen deficiency and repeatedly low testosterone levels due to pathological disorders of the reproductive axis. On a public health level, the abrupt rise in testosterone prescriptions is concerning, particularly since approximately 25% of men who received new testosterone prescriptions did not have a testosterone level obtained in the year prior to the testosterone prescription [4 & ]. It is also possible that the public may view testosterone treatment as a way to prolong life, as several studies reported that low serum testosterone levels are associated with increased mortality in older men [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , although others did not [25] [26] [27] [28] [29] [30] [31] . However, it is unclear if there is a causal association between low testosterone and mortality or if low testosterone is merely a biomarker of poor health and survival. The purpose of this study is to review recent studies on low testosterone and mortality and assess current evidence regarding low testosterone as a biomarker for poor health or as a deficiency that independently contributes to mortality. If low testosterone is a biomarker of medical morbidity, then testosterone levels would decrease with acute and chronic illness and low testosterone would be a risk factor for mortality. If, on the contrary, low testosterone in older men is a deficiency that is causally associated with mortality, then low testosterone would be an independent risk factor for mortality and testosterone replacement would decrease mortality in men with low testosterone levels.
TESTOSTERONE IN OLDER MEN
Testosterone levels in men begin to decline in middle age and continue to slowly decline with age with greater decreases in free testosterone than in total testosterone [32, 33] . However, in contrast to menopause, in which there is cessation of ovarian estrogen secretion, testicular testosterone secretion decreases, but does not cease entirely. Furthermore, the decline in testosterone levels with aging is variable with greater decreases in testosterone in the chronically ill, obese, or men taking medications that decrease testosterone levels [34] [35] [36] [37] , but no decline in testosterone in some healthy older men [38] . In addition, testosterone levels drop abruptly with acute illness such as myocardial infarction, sepsis, or trauma. Despite the decline in testosterone levels with aging, most healthy elderly men have testosterone levels within the normal range for younger men.
Symptoms and signs of low testosterone include decreased libido and erectile function, irritability, fatigue, decreased concentration, increased fat mass, decreased muscle mass, and bone loss [39] . Most of these manifestations are nonspecific and could also be due to advanced age, medical illness, chronic pain, or depression. The only approved indication for testosterone treatment is a diagnosis of hypogonadism, which is based on repeated low testosterone levels obtained in the morning and signs and symptoms of androgen deficiency [40] . Repeated low testosterone levels are required as testosterone levels may fluctuate day to day. Since testosterone levels in older men are likely to be influenced by acute or chronic illness and medications, the diagnosis and management of hypogonadism in older men is more complex than in younger men, with a risk of overdiagnosis in older men if an appropriate assessment is not done [39] .
ENDOGENOUS TESTOSTERONE AND MEDICAL MORBIDITY
Testosterone levels decrease in men with acute illness and normalize following recovery from illness [41] . Low testosterone levels are also associated with chronic medical conditions, such as the metabolic syndrome, diabetes, dyslipidemia, hypertension, renal failure, frailty, malignancy and cardiovascular events [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] . A meta-analysis of endogenous testosterone and cardiovascular events found that higher testosterone levels were associated with a decreased risk for cardiovascular events in men above 70 years of age, with a hazard ratio of 0.84 [95% confidence interval (CI) 0.76-0.92], but not in younger men, with a hazard ratio of 1.01 (95% CI 0.95-1.08) [44] . The association of testosterone with cardiovascular outcomes may be related to its effects on insulin resistance, inflammatory markers, endothelial function, and angiogenesis [49, [52] [53] [54] .
ENDOGENOUS TESTOSTERONE AND MORTALITY
The most recent meta-analysis of testosterone and mortality, which was published in 2011, reported that low testosterone was associated with increased allcause mortality with a hazard ratio of 1.35 (95% CI 1.13-1.62) [55] . Mortality risk was greater in older men and men with lower testosterone levels. However, the studies in the meta-analysis had significant heterogeneity, which suggests that the results could have been influenced by baseline differences in the cohorts. Since the publication of this meta-analysis, several additional studies [5] [6] [7] [8] [9] [10] [11] 13, 16, 17, 19, 20, [24] [25] [26] 29, [56] [57] [58] , which include over 25 000 men, have been published, with the results summarized as follows.
From 2011 to 2012, nine studies were published that examined the association between testosterone
KEY POINTS
Most observational studies have reported an association between low testosterone and increased mortality.
Endogenous testosterone may have an optimal serum range, with increased mortality risk at levels above or below this range.
In recent observational studies, T-treated men had an increased risk for cardiovascular events, with greater risks in older men (>65) and men with prevalent heart disease.
A conservative use of testosterone is warranted in men with prevalent cardiovascular disease (CVD) due to recent reports of increased adverse cardiovascular events in T-treated men with prevalent CVD.
Current research cannot establish if low testosterone is causally associated with mortality or is merely a marker of poor health. Testosterone, aging and survival Shores and Matsumoto and all-cause and cardiovascular mortality. (Table 1) Seven studies found an association between low total or free testosterone and all-cause or cardiovascular mortality [6, [8] [9] [10] [11] 26, 58] , whereas two studies did not [7, 25] . In studies since then, a small study found no association between repeated measures of T, estradiol, dihydroepiandrostene, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) with mortality [27] . Another study of 963 men with prostate cancer followed for a median of 12 years, found no association between prediagnosis androgen levels and outcomes of prostate-cancer mortality and all-cause mortality [28] . In contrast, low total testosterone was significantly associated with all-cause mortality in a study of diabetic men, with a hazard ratio of 2.02 (95% CI 1.2-3.4) [5] . In a large study of 3690 men, total and free testosterone had curvilinear associations with mortality [12] , with the third quartile compared to the first quartile associated with the least risk, with a hazard ratio of 0.78 (95% CI 0.65-0.94) for total testosterone and 0.72 (95% CI 0.60-0.87) for free T.
TESTOSTERONE TREATMENT AND MEDICAL MORBIDITY
Testosterone treatment is associated with decreases in cholesterol, obesity, inflammatory markers, insulin resistance, and improvements in sexual function, muscle mass and strength [59] [60] [61] [62] . Until recently, clinical trials had not reported that testosterone treatment was associated with increased serious adverse effects [63] [64] [65] . However, a recent testosterone treatment study of mobility-impaired elderly men, mean age 70, was stopped due to an increase in self-reported cardiovascular adverse events in the T-treated men [66, 67] . The study used higher doses of testosterone and more than 50% of the T-treated men had prevalent CVD. The risk for cardiovascular events was associated with higher free testosterone levels following treatment, but was not associated with traditional risk factors for CVD. In contrast, in another study involving a similar cohort of near-frail and frail elderly men, 65 years or older, who used a lower dose of T, there was no increase in cardiovascular adverse events [68] . Although not definitive, these results suggest that frail elderly men with underlying CVD may be at increased risk for adverse cardiovascular events and that high doses be used cautiously and testosterone levels monitored during treatment.
TESTOSTERONE TREATMENT, MORTALITY, AND SERIOUS CARDIOVASCULAR ADVERSE OUTCOMES IN OBSERVATIONAL STUDIES
Over the past 2 years, four observational studies examined the association of testosterone treatment with adverse cardiovascular events and mortality [5,69,70 && ,71 & ] (Table 2 ). In a study conducted in a Veterans Affairs healthcare system of 1031 veterans with low testosterone levels, T-treated men had a lower mortality of 10.3 vs. 20.7% compared to the untreated men [69] . These results remained significant after adjusting for age and medical comorbidities, with a hazard ratio of 0.61(95% CI 0.42-0.88) for testosterone treatment compared to no treatment. Strengths of this study are that it used a propensity score analysis to adjust for nonrandomization to treatment and conducted a sensitivity analysis in which men who died within the first year were excluded from the study to minimize the potential effect of acute illness. Weaknesses of the study are that there was no information available on indications for testosterone treatment or presence of hypogonadal symptoms and limited information on follow-up testosterone levels [72] .
In another Veterans Affairs study, men with low testosterone levels, who had cardiac catheterization, were followed for composite events of myocardial infarction (MI), stroke, and all-cause mortality [70 && ]. After adjusting for confounders and coronary artery disease, testosterone treatment was associated with an increased risk for adverse events with hazard ratio of 1.29 (95% CI 1.04-1.58). Strengths of the study are that it adjusted for changes in confounders over time and that it is the largest observational study of T-treated men with low testosterone levels.
Weaknesses of the study are that there was no information available on indications for testosterone treatment or presence of hypogonadal symptoms, and limited information on follow-up testosterone levels. Another limitation is that the men had high medical morbidity with more than 50% with coronary artery occlusion, diabetes and obesity, which makes it difficult to generalize these results to healthier men. The different results of the two Veterans Affairs studies may be related to differences in prevalent heart disease, as the study that reported increased cardiovascular risks associated with testosterone treatment had a high prevalence of heart disease of 59% [70 && ], whereas the study that reported no increased risk with testosterone treatment had a 21% prevalence of heart disease [69] .
A small observational study examined mortality in T-treated and untreated men with low testosterone level, type II diabetes and CVD (42% prevalence). Men who died within the first 6 months or who had less than 1 year of testosterone treatment were excluded from the study. testosterone levels were monitored following treatment to achieve levels in the mid-upper normal range, and 67% of the men had levels above 519 ng/dl (18 nmol/l). In unadjusted analyses, the untreated men had a higher mortality of 19.2 vs. 8.4% in the T-treated men [5] . After adjusting for medical morbidity, the untreated men had a greater risk for all-cause mortality with a hazard ratio of 2.3 (95% CI 1.3-3.9). Strengths of this study were that T-treated men had symptoms of hypogonadism and serum testosterone levels were monitored to achieve physiologic levels. Limitations were the small number of treated men (n ¼ 64), lack of adjustment for the propensity for treatment, and exclusion of men treated for less than 1 year, which may create a survivor bias as it eliminates men who died within the first year of testosterone treatment.
Finally, a recent large cohort study of 55 593 men examined nonfatal MI occurring 1 year before prescription and 90 days after an initial testosterone prescription [71 & ]. The risk for MI was significantly greater following testosterone treatment than in the year prior to testosterone treatment with a greater risk in older men (>65) and in men who had a history of coronary heart disease ( Table 2 ). Strengths of this study are that it is the largest study to date of testosterone treatment and that it adjusted for confounding by utilizing each patient as its own control by comparing pre to post-treatment events. Limitations of this study are that testosterone levels before treatment were unknown, time window of evaluation after testosterone prescription was relatively short, compliance with testosterone prescription was not known, and there was no information regarding indications for testosterone treatment, symptoms of hypogonadism or testosterone levels during treatment.
TESTOSTERONE TREATMENT AND MORTALITY IN CLINICAL TRIALS
Three meta-analyses of testosterone treatment trials [63] [64] [65] found no association between testosterone treatment and mortality or major adverse events. In contrast, a recent meta-analysis [73 && ] of nearly 3000 men found a significant association between testosterone treatment and composite cardiovascular events with an overall hazard ratio of 1.54 (95% CI 1.09-2.18) [73 && ]. A similar hazard ratio of 1.42 (95% CI 0.7-2.89) was reported for cardiovascular mortality, but due to a loss of power the estimate was no longer significant. There was no association with baseline serum testosterone level and adverse outcomes. Industry-sponsored trials reported less risk for composite cardiovascular events with a hazard ratio of 0.89 (95% CI 0.50-1.60) than nonindustry-funded trials with a hazard ratio of 2.06 (95% CI 1. 34-3.17 ).
SUMMARY OF STUDIES OF TESTOSTERONE AND MORTALITY
Since 2011, 13 studies of endogenous testosterone and mortality were published, with nine studies reporting an association between low total or free testosterone and mortality [5] [6] [7] [8] [9] [10] [11] [12] 26] , whereas four did not [7, [25] [26] [27] [28] . A noteworthy result from observational studies was that endogenous testosterone had a nonlinear association with mortality, suggesting an optimal range for androgens [12] . In two large observational studies, testosterone treatment was associated with increased cardiovascular events [70 & 
,71
& ], with short-term testosterone prescription associated with MI, particularly in older men (>65) and younger (<65) and older men with CAD, whereas younger men without CAD did not have an increased risk for MI following testosterone prescription [71 & ]. In a T-treatment trial, elderly, mobility-impaired men with prevalent CVD who were treated with high-dose testosterone had increased self-reported cardiovascular adverse events, whereas another trial in a similar group of older men did not [66, 67] . Finally, in a recent meta-analysis of T-treatment trials, testosterone treatment was associated with an increased risk for adverse cardiovascular events [73 && ]. Although existing studies have limitations, the results of these studies suggest that older men and men with underlying CVD may be at greater risk for serious adverse cardiovascular events associated with testosterone treatment.
IS LOW TESTOSTERONE IN OLDER MEN A BIOMARKER OF POOR HEALTH OR A DEFICIENCY?
Low testosterone appears to be a biomarker of poor health in older men as it is associated with acute and chronic medical conditions [41] [42] [43] and is a risk factor for mortality [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Testosterone may act as a biomarker of illness, similar to other hormones that are biomarkers of illness, such as thyroid hormone (free T3), which declines with illness severity and predicts mortality [74, 75] . Although past cohort studies of low testosterone and mortality have attempted to adjust for medical morbidity, due to the observational study design, there may be some unmeasured marker of medical illness, which explains the association between low testosterone and mortality.
In some older men, low testosterone levels could also reflect a deficiency state. Men with severely low levels of T, such as in hypopituitarism or Klinefelter's syndrome, benefit clinically from testosterone replacement [76, 77] . However, in older men with borderline low testosterone levels, it is less clear if testosterone treatment is beneficial. First, the exact threshold for low testosterone in older men remains controversial [78] . Second, in older men, low testosterone is likely to be related to potentially reversible medical conditions and in such men efforts should first be made to treat the underlying medical condition [39] . Finally, consensus recommendations are that testosterone treatment be reserved for hypogonadal men with repeated low testosterone levels and signs and symptoms of low T. However, on a public health level, testosterone treatment in older men is problematic as a recent study found that many T-treated men (25%) did not have a testosterone level obtained prior to treatment [4 & ]. Finally, it is likely that risks related to testosterone treatment in older men differ from risks in younger men and the risks for serious adverse outcomes, such as cardiovascular events, aggressive prostate cancer and mortality are unclear at this time [79] .
On the basis of current research, it is not clear whether the association between low testosterone and mortality indicates that low testosterone is a biomarker for poor health and survival or if low testosterone is a deficiency that is causally linked to mortality. Existing evidence provides the most support for low testosterone being a biomarker of poor health and perhaps mortality. However, it is less clear that testosterone is causally associated with mortality or if testosterone replacement provides a survival benefit. Ongoing studies that may help to clarify this question include an National Institute of Aging-sponsored multisite testosterone treatment trial in older hypogonadal men. However, this trial was not designed or powered to assess cardiovascular risks or mortality. In addition, the National Institute of Aging has sponsored three pharmaco-epidemiological studies to assess adverse effects of testosterone treatment in differing patient populations. The results of these studies should help to clarify if there are subsets of men who may be more likely to benefit or be harmed from testosterone treatment and help to inform the design of subsequent randomized controlled trials.
CONCLUSION
Although low serum testosterone levels are associated with increased mortality in several observational studies, the significance of this is unclear, as observational studies cannot establish a causal relationship, due to the possibility of residual confounding. A long-term, prospective, randomized controlled trial is needed to clarify the risks and benefits of testosterone treatment. These are significant public health questions given the increasing number of older men with low testosterone levels and the 'epidemic' in testosterone prescribing which has occurred over the past several years [80] .
